RxDoctor Payments Data

James Ramicone, DO

Clinical Cardiac Electrophysiology · Parma, OHNPI 1366481830

Payments from drug & device makers

$11,513in general payments, 2019–2025

Across 385 payments — averaging $29.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Medtronic$2K
  • Boston Scientific$2K
  • Atricure, Inc.$496
  • Biosense Webster, Inc.$426
  • Novartis$160
  • plus $1K from 22 others

What the payments were for

  • Travel & lodging$5,18845%
  • Food & beverage$6,30255%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,513 in reported general payments places this provider in the 30th percentile of 159 clinical cardiac electrophysiology providers in Ohio.

See all clinical cardiac electrophysiology providers in Ohio

Medicare billing

Part B allowed, 2024
$205,559
Medicare patients
1,406
Services billed
3,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban722$850,329
XareltoRivaroxaban297$335,750
MultaqDronedarone Hcl114$134,484
EntrestoSacubitril/Valsartan34$52,164
Dofetilide147$27,334
Flecainide Acetate392$14,695
Amiodarone Hcl256$11,542
Metoprolol Succinate588$8,706
Propafenone Hcl ErPropafenone Hcl17$6,171
BrilintaTicagrelor33$4,980
Mexiletine Hcl14$4,680
Midodrine Hcl25$3,877
Atorvastatin Calcium320$3,366
Metoprolol Tartrate485$2,930
Diltiazem 24hr Er (Cd)Diltiazem Hcl74$2,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$139$850,329722 claims
Johnson & JohnsonXarelto$92$335,750297 claims
Sanofi-aventis U.S. LLCMultaq$28$134,484114 claims
NovartisEntresto$160$52,16434 claims
AstraZenecaBrilinta$138$4,98033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 159 clinical cardiac electrophysiology providers in Ohio.

Other clinical cardiac electrophysiology in Parma

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →